Fig. 7: ATR inhibitor AZD6738 enhances antitumor efficacy of oxaliplatin in PAK6 overexpression cell line xenograft. | Cell Death & Disease

Fig. 7: ATR inhibitor AZD6738 enhances antitumor efficacy of oxaliplatin in PAK6 overexpression cell line xenograft.

From: PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

Fig. 7: ATR inhibitor AZD6738 enhances antitumor efficacy of oxaliplatin in PAK6 overexpression cell line xenograft.The alternative text for this image may have been generated using AI.

a Tumor picture for each group was displayed. b Tumor growth of indicated 803 xenografts in each group. c Animal weight for indicated treatments. d HE staining and IHC staining of PAK6, RAD51, γH2A.X, and cleaved caspase 3 for the tumor isolated from the indicated treatments. Data presented as mean ± SD of three independent replicates. OX: oxaliplatin; ATRi: ATR inhibitor AZD6738; *: P < 0.05, ns: no statistical difference.

Back to article page